(R)-3-Cyanomethyl-Pyrrolidine-1-Carboxylic Acid Tert-Butyl Ester

In the synthesis of P2X3 receptor antagonists currently under Phase II clinical evaluation for refractory chronic cough, the N-Boc-protected (R)-3-cyanomethylpyrrolidine serves as the entry point to a chiral 3-(2-aminoethyl)pyrrolidine arm. The downstream sequence removes the Boc group under anhydrous HCl in dioxane (4.0 M, 2.5–3.0 equiv) at 0–5 °C within 45 min, then reduces the nitrile in methanolic ammonia over Raney cobalt (Ra-Co, Cr-doped, 8% w/w on substrate) at 12 bar H₂ and 65 °C. The free amine is captured in situ with a benzyloxycarbonyl (Cbz) group to prevent intramolecular cyclization. Production-scale batches routinely encounter an exotherm surge when the internal temperature exceeds 72 °C, generating 0.3–0.8% of the de-ethylated pyrrolidine impurity that co-elutes with the product on cation-exchange HPLC (USP L9 column, 0.05 M phosphate buffer pH 6.8 / acetonitrile 85:15). The target 99.2% ee is verified by chiral SFC (Chiralpak IG-3, 4.6 × 150 mm, 3.0 mL/min CO₂ / methanol with 0.1% diethylamine). In the final drug substance synthesis, the Cbz-protected amine is coupled to a tetrahydro-pyrido-pyrimidine carboxylic acid using HATU (1.15 equiv) and N,N-diisopropylethylamine (3.0 equiv) in DMF at –20 °C, keeping racemization below 0.1%. The ultimate oral tablet formulation contains the P2X3 antagonist as a monohydrochloride salt at 45 mg or 75 mg dose strengths with mannitol and crospovidone, tested for dissolution per USP 〈711〉 Apparatus II at 50 rpm in 0.01 N HCl. Controls follow ICH M7 Option 4 for the nitrile-containing mutagenic impurity, with a purge factor assessment based on the reduction’s demonstrated 99.8% conversion in three consecutive commercial lots.

What Are the Kinetic Limits of Hydrogenating (R)-3-Cyanomethyl-Pyrrolidine to the Aminoethyl Derivative?

The catalytic hydrogenation that converts the cyano group to a primary amine is the most thermally scrutinized unit operation in this intermediate’s downstream processing. On a 500 L Hastelloy C-22 autoclave equipped with a hollow-shaft gas-induction impeller (Ekato PHASEJET, 850 rpm tip speed 3.8 m/s), the reaction is charged with (R)-1-Boc-3-cyanomethylpyrrolidine (42 kg, 199.7 mol), methanol (210 L), and 30% w/w aqueous ammonia (8.4 L, 134 mol NH₃) and pressurized with nitrogen to 3 bar for leak check before hydrogen introduction. Raney cobalt 2724 (Grace Davison, 3.36 kg dry basis, presettled in methanol) shows higher selectivity over Raney Ni at pressures below 15 bar, delivering a 96:4 primary amine-to-secondary amine ratio versus 88:12 for W-2 Raney Ni under identical conditions. The half-life of the cyano group at 65 °C is 18 min, while at 75 °C it drops to 8 min but is accompanied by detectable N-Boc cleavage (0.15%/h). Plant runs enforce a strict ≤68 °C jacket set point with a ramp rate of 1.5 °C/min and maintain a hydrogen uptake rate of 0.12–0.18 mol H₂ · kg⁻¹ cat · min⁻¹. When the agitation fails during one documented campaign, stagnant catalyst pocket formation triggered a delayed exotherm, raising the batch temperature to 104 °C and generating 4.7% total de-Boc and ring-opened byproducts; the lot was rejected against the internal specification of ≤1.0% total impurities. Post-filtration, the catalyst is pyrophoric and must remain solvent-wet until quenched with dilute sulfuric acid (2% v/v). The resulting (R)-3-(2-aminoethyl)pyrrolidine-1-carboxylic acid tert-butyl ester is isolated as the hemisulfate salt after solvent switch to isopropyl acetate and polishing filtration through a 0.45 µm PTFE membrane. The solid exhibits a differential scanning calorimetry endotherm at 142.5 ± 1.2 °C (DSC, 10 °C/min, N₂) with a purity by HPLC area percent of 99.86% (UV 205 nm, C18, 150 × 4.6 mm, 1.0 mL/min, water/acetonitrile with 0.05% TFA). This amine intermediate subsequently enters amide coupling cascades for CNS-penetrant histamine H3 receptor antagonists and orexin-2 receptor agonists where the (R)-configuration is essential for target residence time exceeding 45 min in radioligand dissociation assays.

Phosphoramidite Ligands Derived from Enantiopure 3-Aminomethylpyrrolidine Scaffolds

The primary amine obtained after Boc removal can be functionalized with 2-diphenylphosphinobenzoic acid to yield a chiral phosphine-amide ligand that forms an active palladium precatalyst for asymmetric allylic alkylation of 1,3-diphenylprop-2-enyl acetate with dimethyl malonate. In a representative protocol, the free amine (1.0 equiv) is treated with 2-diphenylphosphinobenzoic acid N-hydroxysuccinimide ester (1.05 equiv) in dichloromethane containing triethylamine (1.2 equiv) at –10 °C for 2 h, achieving 94% isolated yield after silica gel chromatography (ethyl acetate/hexane 2:1). The ligand, when combined with [Pd(η³-allyl)Cl]₂ (2 mol% Pd), catalyzes the reaction at 23 °C within 6 h with 92% ee as measured by chiral HPLC (Chiralcel OD-H, 0.5 mL/min, hexane/isopropanol 95:5). The tert-butyl carbamate group remains intact during the catalytic cycle and contributes to steric differentiation in the chiral pocket; substitution with a benzyl or methyl carbamate reduces enantioselectivity by 12–18% ee points. Current scale-up to 50 g batches in a Kilo Lab jacketed reactor (Büchi GlasUster 15 L) is limited by the air-sensitivity of the phosphine, requiring Schlenk-line operations and continuous nitrogen sweep at 0.3 L/min. Industrial end-use products are non-racemic building blocks for fragrance-grade musks (e.g., (--)-ambroxide precursors) and active pharmaceutical ingredients that rely on enantioenriched quaternary carbon centers constructed via this catalytic manifold. Quality control includes ³¹P NMR (202 MHz, CDCl₃) with chemical shift acceptance range of –12.5 ± 0.5 ppm and residual palladium determination by ICP-MS (≤10 ppm per ICH Q3D Elemental Class 2A limit).

A parallel stream exploits the deprotected aminoethylpyrrolidine as a key synthon for integrin αvβ3 receptor antagonist pharmacophores containing the guanidinium-isoxazoline motif. The (R)-configured amine undergoes reductive amination with 4-hydroxybenzaldehyde in the presence of sodium triacetoxyborohydride (1.4 equiv) and acetic acid (1.0 equiv) in 1,2-dichloroethane at 20 °C over 16 h. The benzyl alcohol intermediate is then oxidized to the aldehyde with Dess-Martin periodinane (1.2 equiv) and condensed with 2-amino-2-thiazoline in refluxing ethanol to install the guanidinium mimic. Pilot-scale campaigns have documented formation of a dimeric Schiff-base byproduct when the water content exceeds 0.05% during the condensation step; therefore, the aldehyde solution is dried over activated 3 Å molecular sieves for 4 h before the thiazoline addition. The final peptidomimetic is isolated as the trifluoroacetate salt with 98.5% chromatographic purity and a specific rotation of [α]D²⁰ +22.6° (c 1.0, MeOH). Tablet formulations (immediate release, 25 mg free base equivalent) are coated with Opadry II (4.0% w/w weight gain) and meet ICH Q1A(R2) accelerated stability criteria at 40 °C/75% RH for 6 months with no new impurity exceeding 0.2%.

Alkylation-Induced Chirality Transfer Remains Sensitive to Solvent Dielectric

When the N-Boc-(R)-3-cyanomethylpyrrolidine is deprotonated with lithium bis(trimethylsilyl)amide (LiHMDS, 1.1 equiv, 1.0 M in THF) at –78 °C and alkylated with methyl iodide (1.5 equiv), a quaternary stereocenter is generated at the 3-position with retention dominated by the configuration of the pyrrolidine ring. The diastereomeric ratio (dr) measured after aqueous quench and GC analysis (Agilent J&W DB-5, 30 m × 0.25 mm, 0.25 µm, 10 °C/min from 100 to 280 °C) is 93:7 in THF but drops to 78:22 in 1,3-dimethyl-2-imidazolidinone (DMI, dielectric constant 37.6) at the same temperature. The major diastereomer can be further elaborated to (R)-3-(1-aminoethyl)-3-methylpyrrolidine, a fragment of certain selective glucocorticoid receptor modulators (SGRMs) that lack the metabolic instability of the classic phenylaminopyrimidine core. Multi-kilogram batches installed an inline FTIR probe (Mettler Toledo ReactIR 15 with DiComp diamond ATR) to monitor the LiHMDS addition via the disappearance of the N-H stretch at 3450 cm⁻¹, achieving endpoint control within ±0.5% of the theoretical charge. The alkylated intermediate is carried forward without isolation through a one-pot nitrile reduction with borane-dimethyl sulfide complex (3.0 equiv) in THF, followed by methanolic HCl to cleave the B–N complex and Boc group simultaneously. The crude amino alcohol is crystallized as the dibenzoyl-L-tartrate salt to upgrade the ee from 90% to 99.7%. Residual boron levels in the final salt must not exceed 50 ppm as determined by ICP-OES, since boron interferes with the downstream Suzuki coupling used to assemble the full SGRM scaffold. These chemistry, manufacturing, and controls (CMC) data have been compiled in a Type II drug master file (DMF) submitted to the US FDA with a RESTful application programming interface (API) for electronic Common Technical Document (eCTD) section 3.2.S.2.2.

A conformationally constrained β-turn mimic incorporating the (R)-3-aminomethylpyrrolidine scaffold is assembled on 2-chlorotrityl chloride resin (loading 1.2 mmol/g) using standard Fmoc solid-phase peptide synthesis. The Boc-protected aminoethylpyrrolidine building block is dissolved in N-methylpyrrolidone (NMP) at 0.4 M and coupled to a pre-formed tripeptide with HATU (4.0 equiv relative to free resin sites) and 0.4 M 2,4,6-collidine in DMF, double-coupling for 40 min each. Boc removal on solid phase is achieved with trifluoroacetic acid/triisopropylsilane/water (95:2.5:2.5 v/v/v, 2 × 30 min). The peptidomimetic is cleaved from the resin and globally deprotected, then purified by preparative RP-HPLC (C18, 250 × 50 mm, 100 mL/min, gradient of 15–35% acetonitrile over 60 min) to afford the cyclic peptide analog with 97.2% purity by UPLC at 210 nm. Its thermal melting temperature measured by circular dichroism at 218 nm increases by 14 °C compared to the linear precursor, confirming the turn-stabilizing effect of the pyrolidine ring. The lyophilized acetate salt is stored at –20 °C under argon and is intended as an injectable (50 mg/vial) for phase I studies in oncology targeting protein-protein interactions of MDM2/p53. Regulatory starting material designation for the Boc-aminoethylpyrrolidine fragment was established in accordance with ICH Q11 Example 4, with a Q-SAR threshold for the nitrile precursor applied per ICH M7.